Search

Your search keyword '"Toh, H.C."' showing total 19 results
Start Over Author "Toh, H.C." Publication Year Range Last 50 years
19 results on '"Toh, H.C."'

2. 380P Tumour naïve circulating tumour DNA (ctDNA) analysis in patients (pts) with resected colorectal cancer (CRC) in the phase III ASCOLT trial

Author

Day, D., primary, Starus, A., additional, Lamik, A., additional, Sieber, O., additional, Begbie, S., additional, Bonaventura, A., additional, Rai, S., additional, Karanth, N., additional, Underhill, C.R., additional, Nott, L.M., additional, van Hazel, G., additional, van Hagen, T., additional, Wong, M., additional, Saqib, A., additional, Eastgate, M., additional, Srivastav, R., additional, Chia, J., additional, Toh, H.C., additional, Jones, F., additional, and Segelov, E., additional

Published
2022
Full Text
View/download PDF

3. 652O Randomized phase III VANCE study: Gemcitabine and carboplatin (GC) followed by Epstein Barr virus-specific autologous cytotoxic T lymphocytes (EBV-CTL) versus the same chemotherapy as first-line treatment for advanced nasopharyngeal carcinoma (NPC)

Author

Toh, H.C., primary, Yang, M-H., additional, Wang, H-M., additional, Hsieh, C-Y., additional, Chitapanarux, I., additional, Ho, K.F., additional, Hong, R-L., additional, Ang, M-K., additional, Colevas, D., additional, Sirachainan, E., additional, Lertbutsayanukul, C., additional, Ho, G.F., additional, Samol, J., additional, Huang, Z., additional, Tan, C., additional, Ding, C., additional, and Myo, A., additional

Published
2022
Full Text
View/download PDF

7. 586P Minimal residual disease (MRD) detection using a tumour naïve circulating tumour DNA (ctDNA) assay in patients (pts) with resected colorectal cancer (CRC) in the phase III ASCOLT trial

Author

Day, D., Starus, A., Gebski, V., Simes, J., Hayes, T., Padinharakam, S., Strickland, A.H., Briscoe, K., Varma, S., Barnet, M., Jackson, C., Horvath, L.G., Price, T.J., Tebbutt, N., Karki, B., Diakos, C.I., Chia, J., Toh, H.C., Jones, F.S., and Segelov, E.

Published
2023
Full Text
View/download PDF

10. A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC)

Author

Tai, W.M., primary, Yong, W.P., additional, Lim, C., additional, Low, L.S., additional, Tham, C.K., additional, Koh, T.S., additional, Ng, Q.S., additional, Wang, W.W., additional, Wang, L.Z., additional, Hartono, S., additional, Thng, C.H., additional, Huynh, H., additional, Lim, K.T., additional, Toh, H.C., additional, Goh, B.C., additional, and Choo, S.P., additional

Published
2018
Full Text
View/download PDF

12. A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC)

Author

Tai, W.M., primary, Yong, W.P., additional, Lim, C., additional, Low, L.S., additional, Tham, C.K., additional, Koh, T.S., additional, Ng, Q.S., additional, Wang, W.W., additional, Wang, L.Z., additional, Hartano, S., additional, Thng, C.H., additional, Huynh, H., additional, Lim, K.T., additional, Toh, H.C., additional, Goh, B.C., additional, and Choo, S.P., additional

Published
2016
Full Text
View/download PDF

19. Fluctuating lymphocyte chimerism, tolerance and anti-tumor response in a patient with refractory lymphoma receiving non-myeloablative conditioning and a haploidentical related allogeneic bone marrow transplant.

Author

Toh, H.C., Spitzer, T.R., Preffer, F., Alexander, S.I., McAfee, S., Dombkowski, D., Clark, J.S., Colby, C., Saidman, S., Sackstein, R., and Sykes, M.

Subjects
*LYMPHOCYTES, *MOSAICISM, *BONE marrow transplantation
Abstract

A 51-year-old patient with refractory non-Hodgkin lymphoma (NHL) received non-myeloablative conditioning and a two of six (A, B, DR) human leucocyte antigen (HLA) mismatched donor BMT. Post-BMT lymphocytes showed fluctuating T- and natural killer (NK)-cell chimerism, which culminated in mainly donor lymphocytes by Day + 100. Changes in lymphocyte chimerism correlated with antidonor and anti-host responses in mixed lymphocyte reaction (MLR). On Day + 100, a strong anti-host response was observed in MLR in the absence of graftversus-host disease (GVHD), together with near complete regression of the patient's lymphoma. A mild chronic GVHD later developed and, eventually, by 680 days postBMT, the lymphoma had relapsed and MLR reflected a state of global immune unresponsiveness. These observations demonstrate evolving host-versus-graft and graftversus-host tolerance that correlates with fluctuating lymphoid chimerism and graft-versus-lymphoma (GVL) effects, in the absence of severe GVHD. Eventual lymphoma relapse temporally correlated with a generalised immunosuppressed state. [ABSTRACT FROM AUTHOR]

Published
2002
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results